secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0000950170-22-012523
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista FY2022 net loss $82.3M (-$3.36/share); cash $166.2M; sebetralstat Phase 3 on track
--------------------------------------------------------------------------------

- Net loss $82.3M ($3.36 loss per share) vs $46.2M ($2.42) prior year; R&D spend $70.2M.
- Cash & marketable securities $166.2M at April 30, 2022, down from $248.9M; funding into early 2024.
- Sebetralstat Phase 3 KONFIDENT trial enrollment on track; data expected H2 2023. EU orphan designation received.
- KVD824 Phase 2 KOMPLETE trial for HAE prevention on track; data expected mid-2023.
- Appointed Patrick A. Treanor (COO of Pathalys Pharma) to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/0000950170-22-012523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/kalv-20220707.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer